Cargando…
New Drugs for Treating Dyslipidemia: Beyond Statins
Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with famil...
Autores principales: | Ahn, Chang Ho, Choi, Sung Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411552/ https://www.ncbi.nlm.nih.gov/pubmed/25922802 http://dx.doi.org/10.4093/dmj.2015.39.2.87 |
Ejemplares similares
-
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006) -
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022) -
The role of dyslipidemia and statins in venous thromboembolism
por: Ray, Joel G, et al.
Publicado: (2001) -
Prevalence and types of persistent dyslipidemia in patients treated with statins
por: Reiner, Željko, et al.
Publicado: (2013) -
Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)